We are live on ! Find out more
GILD icon

Gilead Sciences

1,575 hedge funds and large institutions have $73.2B invested in Gilead Sciences in 2017 Q4 according to their latest regulatory filings, with 202 funds opening new positions, 535 increasing their positions, 691 reducing their positions, and 116 closing their positions.

New
Increased
Maintained
Reduced
Closed

74% more first-time investments, than exits

New positions opened: 202 | Existing positions closed: 116

5% more funds holding

Funds holding: 1,5041,575 (+71)

1.25% more ownership

Funds ownership: 76.99%78.25% (+1.3%)

10% less capital invested

Capital invested by funds: $81.5B → $73.2B (-$8.37B)

23% less repeat investments, than reductions

Existing positions increased: 535 | Existing positions reduced: 691

40% less call options, than puts

Call options by funds: $1.57B | Put options by funds: $2.63B

46% less funds holding in top 10

Funds holding in top 10: 9652 (-44)

Holders
1,575
Holders Change
+71
Holders Change %
+4.72%
% of All Funds
35.71%
Holding in Top 10
52
Holding in Top 10 Change
-44
Holding in Top 10 Change %
-45.83%
% of All Funds
1.18%
New
202
Increased
535
Reduced
691
Closed
116
Calls
$1.57B
Puts
$2.63B
Net Calls
-$1.06B
Net Calls Change
-$328M
Name Holding Trade Value Shares
Change
Change in
Stake
CCM
551
Compton Capital Management
Rhode Island
$4.37M -$108K -1,420 -2%
AMM
552
American Money Management
California
$4.36M +$3.19M +41,972 +223%
CA
553
Cetera Advisors
Colorado
$4.34M -$495K -6,518 -10%
MA
554
Montag & Associates
Georgia
$4.31M +$838K +11,036 +22%
First Eagle Investment Management
555
First Eagle Investment Management
New York
$4.28M
SI
556
Stephens Inc
Arkansas
$4.27M -$776K -10,214 -15%
SCM
557
Stonebridge Capital Management
California
$4.24M +$902K +11,880 +28%
MAM
558
Martingale Asset Management
Massachusetts
$4.22M -$205K -2,693 -4%
FNBT
559
FineMark National Bank & Trust
Florida
$4.19M +$3.44M +45,277 +342%
CIP
560
Chartwell Investment Partners
Pennsylvania
$4.18M -$68.3K -900 -2%
RC
561
RegentAtlantic Capital
New Jersey
$4.16M +$239K +3,147 +6%
JAM
562
Jolley Asset Management
North Carolina
$4.14M +$30.6K +403 +0.7%
HFS
563
HL Financial Services
Kentucky
$4.12M -$183K -2,416 -4%
BFS
564
Bradley Foster & Sargent
Connecticut
$4.11M -$533K -7,021 -11%
CFB
565
Cullen/Frost Bankers
Texas
$4.07M -$175K -2,304 -4%
RWP
566
RWA Wealth Partners
Massachusetts
$4.03M -$798K -10,513 -16%
SCM
567
Sterneck Capital Management
Missouri
$4.01M -$339K -4,458 -7%
VCM
568
Vision Capital Management
Oregon
$3.94M -$233K -3,067 -5%
CB
569
Commerce Bank
Missouri
$3.88M +$29.8K +393 +0.7%
MCM
570
Monarch Capital Management
Indiana
$3.86M -$123K -1,620 -3%
MYAM
571
Meiji Yasuda Asset Management
Japan
$3.86M -$194K -2,556 -5%
APFBOT
572
Amica Pension Fund Board of Trustees
Rhode Island
$3.85M
MAM
573
Majedie Asset Management
United Kingdom
$3.85M -$1.57M -20,618 -28%
FQ
574
First Quadrant
California
$3.84M -$1.03M -13,563 -20%
BAM
575
Bell Asset Management
Australia
$3.84M +$4.07M +53,599 New

GILD Hedge Fund Activity: Q4 2017 in Review

1,575 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Gilead Sciences (GILD) for Q4 2017, worth a combined $73.2B — down 10% from $81.5B a quarter earlier.

Buyers outnumbered sellers: 202 funds opened new GILD positions and 116 closed out — a net gain of 86 holders — while 535 added to existing stakes and 691 trimmed.

The largest buyer was Capital Research Global Investors, adding an estimated $794M. The largest seller was C WorldWide Group, cutting an estimated $300M.

  • 1,575 institutional investors held Gilead Sciences (GILD) as of Q4 2017, up from 1,504 in Q3 2017.
  • Funds reported $73.2B of Gilead Sciences stock for Q4 2017, down 10% quarter-over-quarter.
  • 202 funds opened new Gilead Sciences positions in Q4 2017 and 116 closed out, a net change of +86 holders.
  • The largest Gilead Sciences buyer in Q4 2017 was Capital Research Global Investors, an estimated $794M added.
  • The largest Gilead Sciences seller in Q4 2017 was C WorldWide Group, an estimated $300M sold.

Based on aggregated 13F filings for Q4 2017.